{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:39:45Z","timestamp":1793176785990,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clgc.2023.12.015","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T05:24:35Z","timestamp":1704777875000},"page":"434-444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Bladder Cancer and the Urinary Microbiome\u2014New Insights and Future Directions: A Review"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6211-3057","authenticated-orcid":false,"given":"Angela E.","family":"Russo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areeba","family":"Memon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clgc.2023.12.015_bib0001","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/nrc3610","article-title":"The microbiome and cancer","volume":"13","author":"Schwabe","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"1085","key":"10.1016\/j.clgc.2023.12.015_bib0002","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/bmj.2.1085.623","article-title":"On the occurrence of micro-organisms in fresh urine","volume":"2","author":"Roberts","year":"1881","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.clgc.2023.12.015_bib0003","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00218-20","article-title":"Advances in understanding the human urinary microbiome and its potential role in urinary tract infection","volume":"11","author":"Neugent","year":"2020","journal-title":"mBio"},{"issue":"6","key":"10.1016\/j.clgc.2023.12.015_bib0004","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ijantimicag.2019.09.009","article-title":"Shotgun metagenomics for microbiome and resistome detection in septic patients with urinary tract infection","volume":"54","author":"Barraud","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.clgc.2023.12.015_bib0005","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3390\/nu13030886","article-title":"The interplay between the gut microbiome and the immune system in the context of infectious diseases throughout life and the role of nutrition in optimizing treatment strategies","volume":"13","author":"Wiertsema","year":"2021","journal-title":"Nutrients"},{"issue":"8","key":"10.1016\/j.clgc.2023.12.015_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002533","article-title":"Revised estimates for the number of human and bacteria cells in the body","volume":"14","author":"Sender","year":"2016","journal-title":"PLoS Biol"},{"key":"10.1016\/j.clgc.2023.12.015_bib0007","unstructured":"Thomas-White K, Forster SC, Kumar N, et al. Culturing of female bladder bacteria reveals an interconnected urogenital microbiota. Nature News. 2018. Accessed: December 26, 2023. Available at: https:\/\/www.nature.com\/articles\/s41467-018-03968-5."},{"key":"10.1016\/j.clgc.2023.12.015_bib0008","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.urology.2018.12.034","article-title":"The urinary microbiome: implications in bladder cancer pathogenesis and therapeutics","volume":"126","author":"Bajic","year":"2019","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.clgc.2023.12.015_bib0009","first-page":"57","article-title":"Mini-review: perspective of the microbiome in the pathogenesis of urothelial carcinoma","volume":"2","author":"Xu","year":"2014","journal-title":"Am J Clin Exp Urol"},{"issue":"3","key":"10.1016\/j.clgc.2023.12.015_bib0010","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3233\/BLC-200277","article-title":"The urinary microbiome and bladder cancer: susceptibility and immune responsiveness","volume":"6","author":"Andolfi","year":"2020","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.clgc.2023.12.015_bib0011","unstructured":"Key Statistics for Bladder Cancer | American Cancer Society. 2023. Accessed December 26, 2023. Available at: https:\/\/www.cancer.org\/cancer\/types\/bladder-cancer\/about\/key-statistics.html."},{"key":"10.1016\/j.clgc.2023.12.015_bib0012","doi-asserted-by":"crossref","first-page":"17022","DOI":"10.1038\/nrdp.2017.22","article-title":"Bladder cancer","volume":"3","author":"Sanli","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.clgc.2023.12.015_bib0013","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1097\/SPV.0000000000001170","article-title":"The impact of local estrogen on the urogenital microbiome in genitourinary syndrome of menopause: a randomized-controlled trial","volume":"28","author":"Lillemon","year":"2022","journal-title":"Female Pelvic Med Reconstr Surg"},{"issue":"5","key":"10.1016\/j.clgc.2023.12.015_bib0014","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat Rev Micro"},{"key":"10.1016\/j.clgc.2023.12.015_bib0015","unstructured":"Li C-F, Wu W-J, Shiue Y-L. Advances in molecular genetics of early-stage urothelial carcinoma. Transl Cancer Res. 2016. Accessed: December 26, 2023. Available at: https:\/\/tcr.amegroups.org\/article\/view\/10762\/html."},{"issue":"1","key":"10.1016\/j.clgc.2023.12.015_bib0016","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clgc.2023.12.015_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575258","article-title":"FGFR3 alterations in the era of immunotherapy for urothelial bladder cancer","volume":"11","author":"Kacew","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.clgc.2023.12.015_bib0018","doi-asserted-by":"crossref","unstructured":"Syed IS, Pedram A, Farhat WA. Role of sonic hedgehog (SHH) signaling in bladder cancer stemness and tumorigenesis\u2014current urology reports. SpringerLink. 2016. Accessed: December 26, 2023. Available at: https:\/\/link.springer.com\/article\/10.1007\/s11934-015-0568-9.","DOI":"10.1007\/s11934-015-0568-9"},{"issue":"2","key":"10.1016\/j.clgc.2023.12.015_bib0019","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3390\/jcm10020205","article-title":"Urogenital schistosomiasis\u2014history, pathogenesis, and bladder cancer","volume":"10","author":"Santos","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.clgc.2023.12.015_bib0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1128\/CMR.12.1.97","article-title":"Relationship between schistosomiasis and bladder cancer","volume":"12","author":"Mostafa","year":"1999","journal-title":"Clin Microbiol Rev"},{"issue":"11","key":"10.1016\/j.clgc.2023.12.015_bib0021","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.molmed.2016.09.003","article-title":"Urinary tract infection: pathogenesis and outlook","volume":"22","author":"McLellan","year":"2016","journal-title":"Trends Mol Med"},{"issue":"3","key":"10.1016\/j.clgc.2023.12.015_bib0022","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3390\/cancers15030809","article-title":"Urinary Eubacterium sp. CAG:581 promotes non-muscle invasive bladder cancer (NMIBC) development through the ECM1\/MMP9 pathway","volume":"15","author":"Zhang","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2023.12.015_bib0023","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.urology.2020.10.013","article-title":"Culture-independent next generation sequencing of urine and expressed prostatic secretions in men with chronic pelvic pain syndrome","volume":"147","author":"Werneburg","year":"2021","journal-title":"Urology"},{"issue":"7","key":"10.1016\/j.clgc.2023.12.015_bib0024","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154944","article-title":"Next-generation sequencing: insights to advance clinical investigations of the microbiome","volume":"132","author":"Wensel","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clgc.2023.12.015_bib0025","doi-asserted-by":"crossref","unstructured":"McLaren MR, Willis AD, Callahan BJ. Consistent and correctable bias in metagenomic sequencing experiments. eLife. 2019. Accessed: December 26, 2023. Available at: https:\/\/elifesciences.org\/articles\/46923.","DOI":"10.1101\/559831"},{"key":"10.1016\/j.clgc.2023.12.015_bib0026","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1479-5876-10-174","article-title":"Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury","volume":"10","author":"Fouts","year":"2012","journal-title":"J Transl Med"},{"issue":"3","key":"10.1016\/j.clgc.2023.12.015_bib0027","doi-asserted-by":"crossref","first-page":"347.e1","DOI":"10.1016\/j.ajog.2015.07.009","article-title":"The female urinary microbiome in urgency urinary incontinence","volume":"213","author":"Pearce","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.clgc.2023.12.015_bib0028","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.3390\/nu11092216","article-title":"Beneficial effects of dietary polyphenols on gut microbiota and strategies to improve delivery efficiency","volume":"11","author":"Kumar Singh","year":"2019","journal-title":"Nutrients"},{"issue":"8","key":"10.1016\/j.clgc.2023.12.015_bib0029","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00192-019-03931-y","article-title":"Bladder urinary oxygen tension is correlated with urinary microbiota composition","volume":"30","author":"Shannon","year":"2019","journal-title":"Int Urogynecol J"},{"issue":"16","key":"10.1016\/j.clgc.2023.12.015_bib0030","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1002\/cam4.2419","article-title":"Dysbiosis signatures of the microbial profile in tissue from bladder cancer","volume":"8","author":"Liu","year":"2019","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.clgc.2023.12.015_bib0031","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/JU.0000000000001336","article-title":"The microbiome of catheter collected urine in males with bladder cancer according to disease stage","volume":"205","author":"Oresta","year":"2021","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2023.12.015_bib0032","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.it.2021.01.003","article-title":"The roles of T cells in bladder pathologies","volume":"42","author":"Wu","year":"2021","journal-title":"Trends Immunol"},{"key":"10.1016\/j.clgc.2023.12.015_bib0033","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.3389\/fimmu.2018.02389","article-title":"\u03b3\u03b4 T lymphocytes: an effector cell in autoimmunity and infection","volume":"9","author":"Shiromizu","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clgc.2023.12.015_bib0034","doi-asserted-by":"crossref","unstructured":"Witherden DA, Johnson MD, Havran WL. Coreceptors and their ligands in epithelial \u03b3\u03b4 T cell biology. Frontiers. 2018. Accessed: December 26, 2023. Available at: https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2018.00731\/full.","DOI":"10.3389\/fimmu.2018.00731"},{"issue":"4","key":"10.1016\/j.clgc.2023.12.015_bib0035","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ccell.2018.03.015","article-title":"The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy","volume":"33","author":"Gopalakrishnan","year":"2018","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.clgc.2023.12.015_bib0036","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nri.2016.42","article-title":"Gut microbiota, metabolites and host immunity","volume":"16","author":"Rooks","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.clgc.2023.12.015_bib0037","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-4419-1599-3_2","article-title":"FOXP3 and its role in the immune system","volume":"665","author":"Kim","year":"2009","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"10.1016\/j.clgc.2023.12.015_bib0038","doi-asserted-by":"crossref","first-page":"73","DOI":"10.14712\/18059694.2016.63","article-title":"Regulatory T cells (TREG) and their roles in immune system with respect to immunopathological disorders","volume":"53","author":"Kond\u0115lkov\u00e1","year":"2010","journal-title":"Acta Medica (Hradec Kralove)"},{"issue":"7","key":"10.1016\/j.clgc.2023.12.015_bib0039","first-page":"1157","article-title":"When human cells meet bacteria: precision medicine for cancers using the microbiota","volume":"8","author":"Zhang","year":"2018","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.clgc.2023.12.015_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103429","article-title":"The complex interplay of gut microbiota with the five most common cancer types: from carcinogenesis to therapeutics to prognoses","volume":"165","author":"Jaye","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2023.12.015_bib0041","unstructured":"Buc E, Dubois D, Sauvanet P, et al. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS One, 2023. Accessed December 26, 2023. Available at: https:\/\/journals.plos.org\/plosone\/article?id=10.1371%2Fjournal.pone.0056964."},{"issue":"10","key":"10.1016\/j.clgc.2023.12.015_bib0042","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrmicro3344","article-title":"The gut microbiota, bacterial metabolites and colorectal cancer","volume":"12","author":"Louis","year":"2014","journal-title":"Nat Rev Micro"},{"issue":"1","key":"10.1016\/j.clgc.2023.12.015_bib0043","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/gutjnl-2015-309800","article-title":"Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer","volume":"66","author":"Yu","year":"2017","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.clgc.2023.12.015_bib0044","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.urolonc.2009.06.002","article-title":"A disproportion of TH1\/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder","volume":"29","author":"Satyam","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2023.12.015_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.568931","article-title":"The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment","volume":"11","author":"Hudson","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.clgc.2023.12.015_bib0046","unstructured":"Fact Sheets | General | Mycobacterium bovis (Bovine Tuberculosis) in Humans | TB | CDC. 2023. Accessed December 26, 2023. Available at: https:\/\/www.cdc.gov\/tb\/publications\/factsheets\/general\/mbovis.htm"},{"key":"10.1016\/j.clgc.2023.12.015_bib0047","unstructured":"Intravesical Therapy for Bladder Cancer. American Cancer Society. 2023. Accessed December 26, 2023. Available at: https:\/\/www.cancer.org\/cancer\/bladder-cancer\/treating\/intravesical-therapy.html."},{"issue":"10","key":"10.1016\/j.clgc.2023.12.015_bib0048","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41585-021-00481-1","article-title":"100 years of Bacillus Calmette-Gu\u00e9rin immunotherapy: from cattle to COVID-19","volume":"18","author":"Lobo","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"6284","key":"10.1016\/j.clgc.2023.12.015_bib0049","doi-asserted-by":"crossref","first-page":"aaf1098","DOI":"10.1126\/science.aaf1098","article-title":"Trained immunity: a program of innate immune memory in health and disease","volume":"352","author":"Netea","year":"2016","journal-title":"Science"},{"issue":"7_suppl","key":"10.1016\/j.clgc.2023.12.015_bib0050","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.2019.37.7_suppl.423","article-title":"Association of the commensal urinary microbiome with response to Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy in nonmuscle invasive bladder cancer","volume":"37","author":"Sweis","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2023.12.015_bib0051","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2023.12.015_bib0052","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2023.12.015_bib0053","doi-asserted-by":"crossref","first-page":"344.e1","DOI":"10.1016\/j.urolonc.2022.02.009","article-title":"The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial","volume":"40","author":"Daneshmand","year":"2022","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2023.12.015_bib0054","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clgc.2023.12.015_bib0055","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4103\/ua.ua_50_23","article-title":"Trimodal therapy versus radical cystectomy for cT2N0M0 urothelial muscle-invasive bladder cancer: single-center experience","volume":"15","author":"Fallatah","year":"2023","journal-title":"Urol Ann"},{"issue":"1","key":"10.1016\/j.clgc.2023.12.015_bib0056","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12894-020-00733-z","article-title":"Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients","volume":"20","author":"Hamid","year":"2020","journal-title":"BMC Urol"},{"issue":"6","key":"10.1016\/j.clgc.2023.12.015_bib0057","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.3390\/cancers15061742","article-title":"Refining the characterization and outcome of pathological complete responders after neoadjuvant chemotherapy for muscle-invasive bladder cancer: lessons from the randomized phase III VESPER (GETUG-AFU V05) trial","volume":"15","author":"Culine","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.clgc.2023.12.015_bib0058","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4111\/icu.20230006","article-title":"Perioperative systemic therapy in muscle invasive bladder cancer: current standard method, biomarkers and emerging strategies","volume":"64","author":"Kim","year":"2023","journal-title":"Investig Clin Urol"},{"issue":"6","key":"10.1016\/j.clgc.2023.12.015_bib0059","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ccell.2021.05.013","article-title":"Eradicating micrometastases with immune checkpoint blockade: strike while the iron is hot","volume":"39","author":"Janjigian","year":"2021","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.clgc.2023.12.015_bib0060","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"issue":"22","key":"10.1016\/j.clgc.2023.12.015_bib0061","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clgc.2023.12.015_bib0062","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clgc.2023.12.015_bib0063","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/cancers13010131","article-title":"Immune checkpoint inhibitors for the treatment of bladder cancer","volume":"13","author":"Lopez-Beltran","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.clgc.2023.12.015_bib0064","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN ovarian 100): an open-label, randomised, phase 3 trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2023.12.015_bib0065","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV\u2011201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2023.12.015_bib0066","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.3390\/jpm12101745","article-title":"Advanced bladder cancer: changing the treatment landscape","volume":"12","author":"Bilim","year":"2022","journal-title":"J Pers Med"},{"issue":"5","key":"10.1016\/j.clgc.2023.12.015_bib0067","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3390\/cells11050803","article-title":"Antibody-drug conjugates in urothelial carcinoma: a new therapeutic opportunity moves from bench to bedside","volume":"11","author":"Ungaro","year":"2022","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.clgc.2023.12.015_bib0068","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.clgc.2023.12.015_bib0069","unstructured":"Furlow B. Enfortumab vedotin plus pembrolizumab nearly doubles PFS, OS in bladder cancer. Cancer Therapy Advisor. 2023. Accessed: December 23, 2023. Available at: https:\/\/www.cancertherapyadvisor.com\/home\/news\/conference-coverage\/european-society-for-medical-oncology-esmo\/esmo-2023\/enfortumab-vedotin-plus-pembrolizumab-nearly-doubles-pfs-os-in-bladder-cancer\/."},{"issue":"4","key":"10.1016\/j.clgc.2023.12.015_bib0070","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.clgc.2023.12.015_bib0071","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clgc.2023.12.015_bib0072","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3390\/cancers12051181","article-title":"Immunotherapy in bladder cancer: current methods and future perspectives","volume":"12","author":"Wo\u0142\u0105cewicz","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.clgc.2023.12.015_bib0073","unstructured":"National Cancer Institute (NCI). Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer. clinicaltrials.gov; Accessed: January 1, 2023, 2023. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03775265."},{"key":"10.1016\/j.clgc.2023.12.015_bib0074","unstructured":"Merck Sharp & Dohme LLC. A phase 3, randomized, open-label study to evaluate perioperative enfortumab vedotin plus pembrolizumab (MK-3475) versus neoadjuvant gemcitabine and cisplatin in cisplatin-eligible participants with muscle-invasive bladder cancer (KEYNOTE-B15\/EV-304). clinicaltrials.gov; 2023. Accessed: January 1, 2023, 2023. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04700124."},{"issue":"4","key":"10.1016\/j.clgc.2023.12.015_bib0075","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/annonc\/mdw675","article-title":"A phase I\/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder","volume":"28","author":"Obara","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2023.12.015_bib0076","unstructured":"University College, London. A phase Ib\/II study to assess the safety and activity of DURvalumab (MEDI4736) in combination with S-488210\/S-488211 vaccine in non-muscle invasive bladder CancEr. clinicaltrials.gov; Accessed: January 1, 2023, 2023. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04106115."},{"key":"10.1016\/j.clgc.2023.12.015_bib0077","unstructured":"Kilari D. A phase 2 study of CAbozantinib in combination With AtezolizumaB as NeoAdjuvant treatment for muscle-invasive BladdEr cancer. clinicaltrials.gov; Accessed: January 1, 2023, 2023. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04289779."},{"key":"10.1016\/j.clgc.2023.12.015_bib0078","unstructured":"University of Utah. Cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible advanced urothelial carcinoma (PemCab). clinicaltrials.gov; Accessed: January 1, 2023, 2023. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03534804."},{"issue":"1","key":"10.1016\/j.clgc.2023.12.015_bib0079","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12964-020-00625-7","article-title":"Role of tyrosine kinases in bladder cancer progression: an overview","volume":"18","author":"Zangouei","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.clgc.2023.12.015_bib0080","unstructured":"Jonsson Comprehensive Cancer Center. Phase II study of radiation therapy and anti-PD-L1 checkpoint inhibitor (durvalumab) with or without anti-CTLA-4 inhibition (tremelimumab) in patients with unresectable, locally advanced, or metastatic urothelial bladder cancer that are ineligible or refusing chemotherapy. clinicaltrials.gov; 2023. Accessed: January 1, 2023. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03601455."},{"key":"10.1016\/j.clgc.2023.12.015_bib0081","unstructured":"National Cancer Institute (NCI). Molecular analysis for therapy choice (MATCH). clinicaltrials.gov 2023. Accessed: January 1, 2023. Available at: https:\/\/clinicaltrials.gov\/study\/NCT02465060."},{"issue":"4","key":"10.1016\/j.clgc.2023.12.015_bib0082","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1464-410X.2012.11720.x","article-title":"Phase II study of everolimus in metastatic urothelial cancer","volume":"112","author":"Milowsky","year":"2013","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.clgc.2023.12.015_bib0083","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12885-018-4059-5","article-title":"Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer","volume":"18","author":"Pulido","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2023.12.015_bib0084","doi-asserted-by":"crossref","unstructured":"Makawita S. A first in human phase I trial of binary oncolytic adenovirus in combination with HER2-specific autologous CAR T cells in patients with advanced HER2 positive solid tumors. clinicaltrials.gov; Accessed: January 1, 2023, 2023. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03740256.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2679"},{"issue":"6","key":"10.1016\/j.clgc.2023.12.015_bib0085","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.3390\/ijms22062818","article-title":"Cell therapies in bladder cancer management","volume":"22","author":"Morales","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clgc.2023.12.015_bib0086","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-061421","article-title":"Prospective observational study of the role of the microbiome in BCG responsiveness prediction (SILENT-EMPIRE): a study protocol","volume":"12","author":"Bieri","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.clgc.2023.12.015_bib0087","unstructured":"Yonsei University. Development of urologic registry for personalized medicine in patients with urologic malignant diseases by analyzing microbiome. clinicaltrials.gov; Accessed: January 1, 2023, 2023. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04625556."},{"key":"10.1016\/j.clgc.2023.12.015_bib0088","unstructured":"Astra Zeneca. A phase III randomized, open-label, multi-center, global study of durvalumab and Bacillus Calmette-Guerin (BCG) administered as combination therapy versus BCG alone in high-risk, BCG na\u00efve non-muscle invasive bladder cancer patients. clinicaltrials.gov; Accessed: January 1, 2023, 2023. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03528694."},{"key":"10.1016\/j.clgc.2023.12.015_bib0089","unstructured":"Sesen Bio, Inc. Open-label, multicenter, Ph 3 [phase 3] study to evaluate the efficacy and tolerability of intravesical ViciniumTMin subjects with non muscle-invasive carcinoma in situ and\/or high-grade papillary disease of the bladder treated with BCG. clinicaltrials.gov; Accessed: January 1, 2023, 2023. Available at: https:\/\/clinicaltrials.gov\/study\/NCT02449239."},{"key":"10.1016\/j.clgc.2023.12.015_bib0090","unstructured":"Karlovitch S. FDA does not approve Vicinium for BCG-unresponsive NMIBC. Targeted Oncol., 2021. Accessed: December 23, 2023. Available at: https:\/\/www.targetedonc.com\/view\/fda-does-not-approve-vicinium-for-bcg-unresponsive-nmibc."},{"key":"10.1016\/j.clgc.2023.12.015_bib0091","unstructured":"Durvalumab and Vicineum in subjects with high-grade non-muscle-invasive bladder cancer previously treated with Bacillus Calmette-Guerin (BCG)\u2014study results: ClinicalTrials.gov. 2023. Accessed December 26, 2023. Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/results\/NCT03258593."},{"key":"10.1016\/j.clgc.2023.12.015_bib0092","unstructured":"Tianjin Medical University Second Hospital. An open label, randomized control study of probiotics administration in the immunotherapy of urothelial bladder carcinoma. clinicaltrials.gov; Accessed: January 1, 2022 2023. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05220124."},{"key":"10.1016\/j.clgc.2023.12.015_bib0093","article-title":"Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer","author":"Fong","year":"2020","journal-title":"Nature News"},{"issue":"12","key":"10.1016\/j.clgc.2023.12.015_bib0094","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41568-022-00513-x","article-title":"Targeting the gut microbiota for cancer therapy","volume":"22","author":"Fernandes","year":"2022","journal-title":"Nat Rev Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323002811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323002811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:27:24Z","timestamp":1793176044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767323002811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1558767323002811"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.12.015","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bladder Cancer and the Urinary Microbiome\u2014New Insights and Future Directions: A Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}